Who are Aloprim's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin B4, Uloric, Uriadec, Febuxostat Tablets, AL, allopurinol sustained-release capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allopurinol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Aloprim — Competitive Intelligence Brief

Aloprim (ALLOPURINOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Xanthine Oxidase Inhibitor [EPC]. Area: Oncology.

marketed Xanthine Oxidase Inhibitor [EPC] Xanthine dehydrogenase/oxidase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aloprim (ALLOPURINOL) — Casper Pharma Llc. Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aloprim TARGET	ALLOPURINOL	Casper Pharma Llc	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	1966-01-01
Vitamin B4	ADENINE		marketed	Calculi Dissolution Agent [EPC]	Phosphatidylinositol 4-kinase, PI4K, Leucine-rich repeat serine/threonine-protein kinase 2, Xanthine dehydrogenase/oxidase	2021-01-01
Uloric	FEBUXOSTAT	Takeda	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	2009-01-01
Uriadec	TOPIROXOSTAT	Senwa Kegaku Kenkyushp	marketed		ATP-binding cassette sub-family G member 2, Xanthine dehydrogenase/oxidase, Xanthine dehydrogenase/oxidase
Febuxostat Tablets	Febuxostat Tablets	Mostafa Bahaa	marketed	Xanthine Oxidase Inhibitor [EPC]
AL	AL	Medecins Sans Frontieres, Netherlands	marketed	xanthine oxidase inhibitor	xanthine oxidase
allopurinol sustained-release capsules	allopurinol sustained-release capsules	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Xanthine oxidase inhibitor	Xanthine oxidase

Recent regulatory actions (last 90 days)

2026-03-13 — Aloprim · FDA · approved · US · Casper Pharma Llc

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Xanthine Oxidase Inhibitor [EPC] class)

Casper Pharma Llc · 1 drug in this class
Mostafa Bahaa · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aloprim — Competitive Intelligence Brief. https://druglandscape.com/ci/allopurinol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab